| Andrew Lansley reveals he has stage 3 disease for which he is currently being treated
Related items from OnMedica Obesity set to rival smoking as UK’s leading cause of cancer, warns charity |
Source: OnMedica
Smartphone app might offer new way to measure blood flow
(Reuters Health) – An experimental smartphone app might be an effective alternative to a traditional method of assessing circulation in people who need surgery to restore normal blood flow to the heart, a small study suggests.
Source: Reuters Medical News
Crash tests confirm safety of rear-facing carseats in rear impact collisions
(Reuters Health) – Infants and toddlers in rear-facing carseats are well-protected even in rear-impact collisions, crash test results suggest.
Source: Reuters Medical News
Going broke midlife tied to increased risk of premature death
(Reuters Health) – Middle-aged adults who lose most of their net worth over a brief period of time are more likely to die prematurely than individuals who hold on to their nest eggs, a U.S. study suggests.
Source: Reuters Medical News
Weight-loss surgery tied to increases in divorces, marriages
(Reuters Health) – Weight loss surgery can affect interpersonal relationships, a Swedish report suggests.
Source: Reuters Medical News
Mom's heart risk higher when baby has heart defect
(Reuters Health) – Mothers of babies with heart defects are themselves at higher-than-average risk for being hospitalized with heart disease later in life, researchers say.
Source: Reuters Medical News
High-flying biotech Loxo tempers bullish view for cancer drug
STAMFORD, Connecticut (Reuters) – In record time, Loxo Oncology developed a novel drug for a wide variety of tumors that share a rare mutation. It recently struck a partnership with Germany’s Bayer . Its stock tripled in the past year.
Source: Reuters Medical News
Pfizer signs deal with Allogene to develop cancer cell therapy
(Reuters) – Pfizer Inc said on Tuesday it signed an agreement with Allogene Therapeutics, a company formed by a consortium in which the drugmaker will hold a 25 percent stake, to further develop its allogenic CAR T cell therapy.
Source: Reuters Medical News
European Medicines Agency to review Sanofi-Regeneron's Dupixent, Cemiplimab
PARIS (Reuters) – The European Medicines Agency (EMA) will review the Dupixent (dupilumab) and Cemiplimab products being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.
Source: Reuters Medical News
Justice Department seeks role in opioid settlement talks
(Reuters) – The U.S. Justice Department on Monday sought court permission to participate in settlement negotiations aimed at resolving lawsuits by state and local governments against opioid manufacturers and distributors.
Source: Reuters Medical News